Switching HIV Treatments: Research

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Show Archived (Historical) Articles

Study Finds More Depression Among People Who Often Switch HIV Medications (July 17, 2007)
From aidsmap.com
COOL Study: The Ultimate Misnomer? (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
The Role of Double-Boosted Protease Inhibitors Still Unclear (August 17, 2006)
In XVI International AIDS Conference
Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
HIV JournalView: Persistent, Low-Level Viremia May Breed Resistance (September 2005)
Whether treatment should be switched in viremic patients depends on the regimen and the viral load level, a new study suggests.
From The Body PRO
Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from The Body PRO
HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
Dual NRTI Plus Efavirenz Regimen Superior to Boosted PI Plus Efavirenz (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part I: Research Update (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part II: Case Studies (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Thrush in People on HAART May Be a Sign of Treatment Failure (February 2005)
In this Spanish study, oral candidiasis (also known as thrush) was found in more than 90% of people whose HAART regimens were no longer working.
In AIDS Patient Care and STDs
Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
In The XV International AIDS Conference, from The Body PRO
Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
Substituting With Tenofovir Decreases the Adverse Effects Seen With Other NRTIs (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
NNRTI Not Working? It May Be Safe to Stop It, One Study Suggests (June 28, 2004)
If a patient has become resistant to the NNRTI in a HAART combination, cutting the NNRTI out of the regimen appears to do no additional harm.
From aidsmap.com
Dual-PI Regimen Preferred Over Single-PI Regimen After Initial PI Failure (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Gastrointestinal Side Effects Lead One in Eight to Change HAART Regimen in First Year of Treatment (November 27, 2003)
More than half of new HAART patients were also found to switch or stop their initial regimens within the first year, often without consulting their doctors.
From aidsmap.com
Dyslipidemia: Change to Tenofovir? (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
To Switch or Not to Switch: When Is It a Question? (September 2003)
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook
"Mono"-Therapy for HIV Infection Using Ritonavir-Boosted Indinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Atazanavir-Based Once-Daily Regimen Successful in Switch From a Twice-Daily PI-Based Regimen (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Simplification Works! Fewer Pills Mean Better Adherence and Quality of Life (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Assessment of Changes in Adherence and Quality of Life After the Simplification of Antiretroviral Treatment (July 2003)
Highlights from the IAPAC Sessions 2003.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Key Therapeutic Decisions in Managing HIV Infection (Spring 2003)
An update on when to start, when to switch and when to stop, from STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Response to a Second Treatment Regimen Following Virologic Failure (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efficacy and Safety of AZT/3TC/ABC (Trizivir) Maintenance Treatment After First-Line Quadruple Induction Therapy; Interim 24-Week Data From AZLF3004/TRISUD (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Pittsburgh: Grant to Fund AIDS Outreach in Black Neighborhoods (November 19, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Successful Switch From Stavudine to Once-Daily Tenofovir Based Regimen in Patients With Fully Suppressed HIV (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Expert Opinion From Barcelona: For Experienced Folks (September/October 2002)
In Positively Aware, from Test Positive Aware Network
Digging Deeper at the Resistance Workshop (August 14, 2002)
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
Expanded Response Analyses of Tenofovir DF Therapy by Baseline Resistance Genotype and Phenotype (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Is Simplification to Triple Antiretroviral Therapy After Viral Suppression With Quadruple Therapy Initiated at the Time of Primary Infection Associated With Increased Low-Level Viral Breakthrough? (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Simplification of Protease Inhibitor-Based Highly Active Antiretroviral Regimens With Abacavir Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Retrospective Analysis of the Use of Tenofovir DF in a Private Practice (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO
Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Long-Term Efficacy and Safety of Emtricitabine (FTC) in HIV-Positive Adults Switching from a Lamivudine (3TC)-Containing HAART Regimen (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Tenofovir DF: A 24-Week Interim Analysis From a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Long-Term Follow-Up of MAINTAVIR Study: Substitution of a NNRTI for Protease Inhibitor in Patients on Combination Therapy with Undetectable Plasma Viral Loads (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
In New England Journal of Medicine
HIV NAT 002.1/002.2: Immediate (IS) Versus Deferred Switching (DS) from ddI/D4T to AZT/3TC in an HIV+ Thai Population and Determine Predictors to Improve Treatment Response to Long-Term Dual Nucleoside Therapy as an Option for Resource-Limited Countries (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Swiss Research Finds That Switching Therapy May Not Lower High Lipid Levels (May 4, 2001)
From Canadian AIDS Treatment Information Exchange
An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
SWATCH Study: A Multicenter Trial of Proactive Treatment Switching. Results at Nine Months of Follow-Up (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
"Switch" Studies for People with Lipodystrophy (August 2000)
In Project Inform Perspective, from Project Inform
The Effects of Hydroxyurea or Placebo Combined with Efavirenz, Didanosine, and Stavudine in Treatment of Naive and Experienced Patients: Preliminary 24-Week Results From the Third Study (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
The ADAM Study: Maintenance Therapy After 50 Weeks of Induction Therapy (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
It Takes Two, Maybe (Spring 2000)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Selected Highlights from the 7th CROI: Combination Drug Studies (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Selected Highlights from the 7th CROI: Studies of Switching Therapy (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.